![](https://d3ilqtpdwi981i.cloudfront.net/8kx5Pljb55FMOOEW6JoEr6A47mg=/0x5:200x263/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/bb/8c/48/bb8c48c3-f3ef-49ac-9c81-bf10801a9ac6/jnccn.jpg)
Article
HSR21-061: Frequency of Oncologists (ONC) Office Visit and Caregiver Burden With Poly(ADP-ribose) Polymerase Inhibitor (PARPi) Versus Chemotherapy (CTX) Among Adult Patients (pts) With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC): Results From a Multi-Country Real-World (RW) Study
Journal of the National Comprehensive Cancer Network
(2021)
Disciplines
Publication Date
March 17, 2021
Citation Information
Reshma Mahtani, M.P. Lux, A. Niyazov, K. Lewis, et al.. "HSR21-061: Frequency of Oncologists (ONC) Office Visit and Caregiver Burden With Poly(ADP-ribose) Polymerase Inhibitor (PARPi) Versus Chemotherapy (CTX) Among Adult Patients (pts) With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC): Results From a Multi-Country Real-World (RW) Study" Journal of the National Comprehensive Cancer Network Vol. 19 Iss. 35 (2021) Available at: http://works.bepress.com/reshma-mahtani/103/